RCUS•benzinga•November 5, 2024 at 02:14 PM

Arcus Biosciences Announces That Domvanalimab Plus Zimberelimab Improved Overall Survival In ARC-10, A Randomized Study In Patients With PD-L1-High Non-Small Cell Lung Cancer; A 36% Reduction In Risk Of Death Was Observed

No summary available.

Read the full article from the original source for complete details and context.

Article published on November 5, 2024 by benzinga